

**In the Claims:**

Claims 1-30 (Cancelled)

31. (Currently Amended): An isolated polypeptide comprising SEQ ID NO: 2, 4 or 6 a ~~member selected from the group consisting of~~

- ~~(a) — an amino acid sequence which has at least 90% identity to SEQ ID NOs:4 or 6;~~
- ~~(b) — an immunogenic fragment of the amino acid sequence of (a), wherein the immunogenic fragment is at least 90% identical to an aligned contiguous segment of SEQ ID NOs:4 or 6; and~~
- ~~(c) — an immunogenic fragment of the amino acid sequence of (a) that matches an aligned contiguous segment of SEQ ID NOs:4 or 6 with no more than five single amino acid substitutions, deletions or additions;~~

~~wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NOs:4 or 6.~~

Claims 32-35 (Cancelled)

36. (Previously Presented): The isolated polypeptide of Claim 35 wherein the isolated polypeptide comprises the amino acid sequence of SEQ ID NOs:4 or 6.

37. (Previously Presented): The isolated polypeptide of claim 35 wherein the isolated polypeptide consists of the amino acid sequence of SEQ ID NOs:4 or 6.

38. (Previously Presented): An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2.

39. (Previously Presented): A fusion protein comprising the isolated polypeptide of Claim 31.

Claims 40-59 (Cancelled)

60. (Currently Amended): An immunogenic composition ~~A vaccine~~ comprising the polypeptide of Claim 31 and a pharmaceutically acceptable carrier.
61. (Currently Amended): An immunogenic composition ~~A vaccine~~ comprising the polypeptide of Claim 38 and a pharmaceutically acceptable carrier.
62. (Currently Amended): The immunogenic composition ~~vaccine~~ of Claim 60, wherein the composition comprises at least one other *Neisseria meningitidis* antigen.

Claims 63-64 (Cancelled)

65. (Previously Presented): A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 31.

Claims 66-67 (Cancelled)

68. (Previously Presented): A therapeutic composition useful in treating humans with *Neisseria meningitidis* comprising at least one antibody directed against the polypeptide of claim 31 and a suitable pharmaceutical carrier.
69. (Previously Presented): A therapeutic composition useful in treating humans with *Neisseria meningitidis* comprising at least one antibody directed against the polypeptide of claim 38 and a suitable pharmaceutical carrier.
70. (Cancelled)
71. (New): The isolated polypeptide of claim 31, wherein the isolated polypeptide is a recombinant polypeptide.